Spotlight
Obituaries
Classifieds
Families First
VCAs Best of Guide
News
Weather
Specialists
Sports
Business
Consumer
Health
Life
Out & About
Login
Program
On WRAL at 11: Memorial Day continues to trend drier. Ahead, meteorologists time out when rain could impact your holiday plans
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by ASCENTAGE PHARMA GROUP INTERNATIONAL
Ascentage Pharma Announces Clinical Data of Lisaftoclax, Which Shows Therapeutic Potential in Venetoclax-Refractory Patients, Selected for Oral Report at ASCO 2025
May 22, 2025
From
ASCENTAGE PHARMA GROUP INTERNATIONAL
Via
GlobeNewswire
Tickers
AAPG
Ascentage Pharma Presents Results from Five Preclinical Studies at 2025 American Association of Cancer Research (AACR) Annual Meeting, Highlighting Strong Synergistic Effects of Olverembatinib Combined with Lisaftoclax
April 28, 2025
From
ASCENTAGE PHARMA GROUP INTERNATIONAL
Via
GlobeNewswire
Tickers
AAPG
Ascentage Pharma To Present Data from Two Clinical Studies at 2025 ASCO Annual Meeting, Including Oral Presentation on Its Key Assets Lisaftoclax and Alrizomadlin
April 23, 2025
From
ASCENTAGE PHARMA GROUP INTERNATIONAL
Via
GlobeNewswire
Tickers
AAPG
Ascentage Pharma Announces Inclusion of Lisaftoclax and Olverembatinib in Chinese Society of Clinical Oncology (CSCO) 2025 Guidelines
April 21, 2025
From
ASCENTAGE PHARMA GROUP INTERNATIONAL
Via
GlobeNewswire
Tickers
AAPG
Ascentage Pharma Reports Full Year 2024 Unaudited Financial Results and Business Updates
March 27, 2025
From
ASCENTAGE PHARMA GROUP INTERNATIONAL
Via
GlobeNewswire
Tickers
AAPG
Ascentage Pharma to Present Five Preclinical Studies from Innovative Pipeline at American Association of Cancer Research (AACR) Annual Meeting 2025
March 25, 2025
From
ASCENTAGE PHARMA GROUP INTERNATIONAL
Via
GlobeNewswire
Tickers
AAPG
Ascentage Pharma to Report Full Year 2024 Financial Results and Provide Corporate Update on March 27, 2025
March 12, 2025
From
ASCENTAGE PHARMA GROUP INTERNATIONAL
Via
GlobeNewswire
Tickers
AAPG
Olverembatinib Granted Breakthrough Therapy Designation for the Treatment of Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)
March 05, 2025
From
ASCENTAGE PHARMA GROUP INTERNATIONAL
Via
GlobeNewswire
Tickers
AAPG
Ascentage Pharma Announces Partial Exercise of Underwriters’ Option to Purchase Additional American Depositary Shares
February 07, 2025
From
ASCENTAGE PHARMA GROUP INTERNATIONAL
Via
GlobeNewswire
Tickers
AAPG
AAPGV
Ascentage Pharma Announces Closing of U.S. Initial Public Offering
January 28, 2025
From
ASCENTAGE PHARMA GROUP INTERNATIONAL
Via
GlobeNewswire
Tickers
AAPG
AAPGV
Ascentage Pharma Announces Pricing of U.S. Initial Public Offering
January 23, 2025
From
ASCENTAGE PHARMA GROUP INTERNATIONAL
Via
GlobeNewswire
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.